Fecundis Lab Competitors

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.

Sartorius is a leading international partner of biopharma research and manufacturing. We help our customers simplify progress from drug discovery to manufacturing so that more people can have access to better medicine. And simplifying progress starts with our employees who move things forward by realizing ambitious ideas and growing alongside with the company. Our product portfolio covers two customer groups: With innovative laboratory instruments and consumables, Sartorius focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. Our broad bioprocess product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with more than 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2025, Sartorius generated sales revenue of around 3.5 billion euros. Currently, more than 14,000 employees from 110+ nations are working for customers around the globe. Join our team, partner or collaborate with us.